Following a highly successful year and several drug discovery milestones using its flagship AI platform, Exscientia are pleased to welcome Andrew Douglas as the new Director of Data Engineering.
Andrew joins Exscientia from Winton Capital, a global investment management and data science company, where he led the design and creation of platforms, algorithms and models to automate data processing, analyse data and predict outcomes as a core element of the firm’s strategic investment approach.
“We’re thrilled to welcome Andrew to the team”, says Adrian Schreyer, CTO at Exscientia. “This is a very exciting time for us, as we are rapidly expanding our talent in computer science and drug discovery in anticipation of rapid growth, so this timing could not have been better.”
Exscientia is at the forefront of artificial intelligence (AI)-driven drug discovery and design. Frontier IP Group plc (LON:FIPP) as a 5% holding in Exscientia as of 30th June 2016.